Therapy for Clostridium difficile infection – any news beyond Metronidazole and Vancomycin?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Therapy for Clostridium difficile infection – any news beyond Metronidazole and Vancomycin?

Published:2017-08-11 Issue:11 Volume:10 Page:1239-1250
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Manthey C.F.¹,Eckmann L.²,Fuhrmann V.³

Affiliation:

1. I. Medical Department, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

2. Department of Medicine, University of California, San Diego, La Jolla, CA, USA

3. Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Funder

This manuscript was not funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2017.1362978

Reference101 articles.

1. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection

2. Clostridium difficile infection: Evolution, phylogeny and molecular epidemiology

3. Fidaxomicin versus Vancomycin forClostridium difficileInfection

4. Bezlotoxumab for Prevention of RecurrentClostridium difficileInfection

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?;Journal of Microbiology, Immunology and Infection;2021-12

2. Characteristics and predictors of treatment failure with intravenous tigecycline monotherapy among adult patients with severe Clostridioides (Clostridium) difficile infection: a single-centre observational cohort study;Diagnostic Microbiology and Infectious Disease;2021-02

3. Akute Gastroenteritis im Kindes- und Erwachsenenalter;Gastroenterologie up2date;2020-12

4. Mechanism of Antibacterial Activity of Bacillus amyloliquefaciens C-1 Lipopeptide toward Anaerobic Clostridium difficile;BioMed Research International;2020-03-04

5. Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota;Antimicrobial Agents and Chemotherapy;2019-12-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3